VVitenta
Medicines · Approvals15 October 2026·Verified source: EMA, MHRA, AJMC

The daily GLP-1 pill Foundayo: already in the US and the UK, now recommended for the EU

What changed

The EMA's committee for human medicines recommended authorising Foundayo (orforglipron, Eli Lilly) in the European Union: a GLP-1 tablet taken once a day, at any time, with or without food, for weight management and type 2 diabetes in adults. In the two weight studies, with 4,740 adults, people lost about 5–11% of their weight after 72 weeks, depending on the dose, compared with 2–2.5% on placebo. The FDA approved Foundayo in the US in April 2026, and the UK's MHRA authorised it on 10 August 2026.

What it means for you

  1. 1In the EU this is a recommendation, not yet an authorisation. The European Commission usually decides within about two months; after that, each country sets the price.
  2. 2In the UK it is available on private prescription. It is not on the NHS while NICE assesses it.
  3. 3If your current treatment works well, there is nothing to change. New options are a conversation with your doctor.

What does not change

Injectable treatments stay the same. The most common side effects reported with Foundayo come from the same family: nausea, vomiting and diarrhoea, mostly when the dose goes up.

Sources

Is something missing on Vitenta?

Tell us what to add or what wasn't clear. Anonymous — no name, e-mail or phone.

What you write reaches only the team and is never shown on the site. Any content change is checked against the official leaflet.

Your suggestion
0/500 characters

Please don't include personal details.